多替阿巴拉米片是治疗药还是阻断药

, the trade name is Triumeq, is a compound drug containing three ingredients: dolutegravir/abacavir/lamivudine, that is, "dolutegravir + abacavir + lamivudine", the dosage is 50mg+600mg+300mg, the total dosage is 950mg.

The approval of dolutegravir was based on data from two pivotal Phase III studies, one of which investigated dolutegravir and abacavir/lamivudine as separate tablets; the other of which investigated fixed doses. Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in dolutea palamid tablets is significantly less than that of the other two drugs, making it less likely to develop drug resistance. Suimeikai has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.

Professor Zhang Fujie, director of the Infection Clinical and Research Center of Beijing Ditan Hospital, said: " At present, global antiviral treatment is gradually entering the era of integrase inhibitors, and fixed-dose combination preparations have become the trend in future treatment. Integrase inhibitors have four main characteristics: stronger antiviral effects, smaller side effects, fewer drug interactions, and less resistance. The launch of Suimeike, a single-pill combination drug containing a new generation of integrase inhibitor DTG, will bring a more convenient and efficient integrase inhibitor combination to Chinese HIV-infected patients, which is a major advancement in China's existing antiviral treatment."

The most common adverse reactions are nausea, vomiting, dizziness, and gastrointestinal discomfort. It is normal to experience side effects when taking medicines. Mild symptoms will gradually disappear over time. For serious gastrointestinal side effects, please seek medical treatment in time. Take medications as directed by your doctor, and do not change the dosage or take other gastrointestinal medications without authorization.

Recommended related hot articles: /newsDetail/85441.html